RRMS

Swank and Wahls diets seen to improve RRMS hand, arm dexterity

The Swank and Wahls diets ā€” two dietary strategies often adopted by people with multiple sclerosis (MS) ā€” were similarly effective at easing functional disability after six months among people with relapsing-remitting MS (RRMS), according to data from a small clinical trial. These functional gains were mostly driven…

Genetic risk found similar between RRMS, PPMS in Swedish study

The risk of developing multiple sclerosis (MS) was similar between first- and second-degree family members of people with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). The findings, which were consistent with previous studies suggesting that genetics and environment are relatively equal contributors to disease risk, also…

Aubagio shifts immune cell balance in RRMS, study reveals

Aubagio (teriflunomide), an approved therapy for relapsing forms of multiple sclerosis (MS), works by shifting the balance between activated subsets of nerve-damaging immune cells to those with immunosuppressive traits, a new study reveals. Further studies to understand how changes in immune cell subsets drive Aubagioā€™s clinical effectiveness will…

Stem cell therapy highly effective in active RRMS: Real-world study

Nearly 80% of adults with highly active relapsing-remitting multiple sclerosis (RRMS) were free of relapses or confirmed disability worsening two years after receiving stem cell transplant, according to a real-world study in Denmark. Moreover, more than two-thirds (69%) of these RRMS patients achieved a clinical outcome called NEDA-3, or…

ACTRIMS 2023: RRMS treatment may ‘give patients a better choice’

New data from a Phase 2 clinical trial testing vidofludimus calcium, Immunic Therapeuticsā€™ novel oral treatment candidateĀ for relapsing-remitting multiple sclerosis (RRMS), show promising safety and efficacy, according to the company’s chief medical officer. The therapy was found to safely reduce brain lesions and prevent disability progression in…

Add-on Supplement May Bolster Interferon Therapies for RRMS

A dietary supplement called Neuroaspis plp10 significantly lowered relapse rates and slowed disability progressionĀ among people with relapsing-remitting multiple sclerosis (RRMS) on interferon beta medications, according to a small clinical trial in Greece. “The results of this study suggest that Neuroaspis plp10 may offer greater benefit to patients with RRMS…

Treatments Seen to Account for Largest Part of MS Financial Burden

Medications account for the majority of costs related to managing multiple sclerosis (MS) in Italy, andĀ secondary-progressive MS (SPMS) is associated with higher treatment and healthcare costs than those forĀ relapsing-remitting multiple sclerosis (RRMS), a study looking at real-world data reported. ā€œA bigger healthcare resource consumption was retrieved for…

#ECTRIMS2022 ā€“ Vumerity Lowers RRMS Activity Over 2 Years

Up to two years ofĀ Vumerity (diroximel fumarate) treatment was generally well-tolerated and led to significant decreases in disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to a final analysis of data from the open-label EVOLVE-MS-1 Phase 3 clinical trial. Indirect comparisons of Vumerity-treated patients against those…

Direct Electrical Stimulation of Brain Found to Ease MS Spasticity

Electrical stimulation of the brain through electrodes placed on the scalp may ease some measures of spasticity for people with relapsing-remitting multiple sclerosis (RRMS), according to results from a small clinical trial. Using this novel route of brain stimulation was shown to impact muscle contractions in patients with spasticity…

More Microscopic Brain Damage Seen in SPMS Than in RRMS

People with secondary progressive multiple sclerosis (SPMS) have more microscopic damage in normal-appearing brain tissue than do patients with relapsing-remitting multiple sclerosis (RRMS), according to a new imaging study. These patients also have a greater number of chronic active lesions than those with RRMS. “Using advanced diffusion MRI…

Natalizumab, Tysabri Biosimilar, Up for Approval in Europe

The European Medicines Agency (EMA) has agreed to review a request to approveĀ Polpharma Biologics‘ biosimilar natalizumab for the treatment of multiple sclerosis (MS). This marks the first time the regulatory agency accepted a marketing authorization application for a biosimilar of Tysabri, anĀ approved MS treatment. “The acceptance…

Smoking Linked to Worse Outcomes in RRMS Patients After 10 Years

Smoking is associated with lower brain volume, more brain lesions, and greater disability and attention deficits among people with relapsing-remitting multiple sclerosis (RRMS) after 10 years,Ā according to a study in Norway. “The findings imply that patients should be advised and offered aid in smoking cessation shortly after diagnosis, to…

Vidofludimus Calcium Safely Reduced RRMS Brain Lesions

Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosisĀ (RRMS), data from the Phase 2 EMPhASIS clinical trial shows. Top-line results from EMPhASIS were reported by the therapy’s developer Immunic Therapeutics in 2020. Researchers at…

Marriage, Education, DMT Affect Patients’ Treatment Adherence

Among people with relapsing-remitting multiple sclerosis (RRMS), those who are married and have more formal education are more likely to take treatments as recommended, according to a new study from Iran. The study, “Effects of Disease-Modifying Treatments discontinuation in patients with Relapsing-Remitting Multiple Sclerosis: A 5…

‘Hidden’ Disabilities Fairly Common at RRMS Diagnosis, Study Finds

Many people newly diagnosed withĀ relapsing-remitting multiple sclerosis (RRMS) experience substantial “hidden disabilities,” such as depression or fatigue, a study highlights. Findings indicate that treatment with disease-modifying therapies generally does not affect the severity of these problems, at least in the short term. “Considering the substantial impact that hidden…

Keto Diet Improved Life Quality of RRMS Patients in Trial

Eating a ketogenic diet ā€” one low in carbohydrates and high in fats ā€” led to markedly less fatigue and depression for people with relapsing-remitting multiple sclerosis (RRMS) in a small clinical trial that was designed to assess the tolerability of the dietary intervention. Measures of disability and quality…

Kesimpta Now Reimbursable for Patients in 2 Canadian Provinces

Kesimpta (ofatumumab) is now accessible to eligible Canadians with relapsing-remitting multiple sclerosis (RRMS) through public drug plans in Ontario and Quebec. The treatment has been included as an exceptional medication under both the Ontario Drug Benefit Exceptional Access Program and the RĆ©gie de lā€™assurance maladie du QuĆ©bec. This…